35 results
8-K
EX-99.1
COYA
Coya Therapeutics Inc
20 May 24
Coya Therapeutics Announces $5 Million Strategic
5:00pm
’ disease progression was measured using the ALSFRS-R scale, a validated rating tool for monitoring the progression of disability in patients with ALS
8-K
EX-99.1
ncngslfkoraw e4h
6 Dec 23
Entry into a Material Definitive Agreement
7:30am
8-K
EX-10.1
4ouiujhwxm 0wri3a5n
14 Jul 23
Departure of Directors or Certain Officers
5:01pm
8-K
EX-10.1
4vk686x0 xhld1yndxc
10 Jul 23
Departure of Directors or Certain Officers
5:08pm
DEF 14A
3pbk6xb0
19 May 23
Definitive proxy
4:31pm
10-K
EX-3.1
odgf6
29 Mar 23
Annual report
4:08pm
10-K
EX-3.2
f7edk6bz o1xk6tab
29 Mar 23
Annual report
4:08pm
10-K
08j ot372s2nh3d5r3e
29 Mar 23
Annual report
4:08pm
424B4
rh9dmc4fqdom2pdowpw
30 Dec 22
Prospectus supplement with pricing info
4:17pm
S-1/A
EX-10.15
prfhzqibuwo0ekv
5 Dec 22
IPO registration (amended)
8:16am
S-1/A
EX-10.1
4etw2khm 8p
5 Dec 22
IPO registration (amended)
8:16am
S-1/A
r7xm9485 ayhd2t
5 Dec 22
IPO registration (amended)
8:16am
S-1/A
EX-3.2
acbg 4p9qa7my28b7obv
5 Dec 22
IPO registration (amended)
8:16am
S-1
EX-3.4
kzns7
18 Nov 22
IPO registration
5:06pm